IVX nice announcement
Invion completes study of INV103 (ala-Cpn10) in patients with systemic lupus (SLE)
Study designed to test safety and biochemical effect of materially higher doses than previous studies
Data from patients’ cells show positive effect after one month of dosing
Study supports larger, longer trials of Cpn10 in patients with autoimmune diseases
Company to focus on partnering the drug asset
going up....
- Forums
- ASX - Day Trading
- Daytrading August 17 pre-market
Daytrading August 17 pre-market, page-25
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)